<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of thyroid eye disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of thyroid eye disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of thyroid eye disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Terry F Davies, MD, FRCP, FACE
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Henry B Burch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas S Ross, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jean E Mulder, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 29, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyroid eye disease (also commonly referred to as Graves' orbitopathy or ophthalmopathy) is an autoimmune disease of the retro-orbital tissues occurring in patients with Graves' disease. This topic review will provide an overview of the natural history and treatment of this disorder. The pathogenesis, clinical features, and diagnosis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7825.html" rel="external">
          "Clinical features and diagnosis of thyroid eye disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          NATURAL HISTORY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The natural history of thyroid eye disease is variable and must be considered in the context of concomitant hyperthyroidism and its therapy [
         <a href="#rid1">
          1-4
         </a>
         ].
        </p>
        <p>
         Untreated thyroid eye disease typically follows a course of progression at variable rates, followed by a plateau or stabilization, and then varying degrees of improvement. The inflammatory manifestations of the disorder (eye irritation and conjunctival and periorbital edema) tend to subside, whereas proptosis (exophthalmos) and extraocular eye muscle dysfunction persist. While mild thyroid eye disease may remit spontaneously, moderate-to-severe disease rarely resolves without treatment.
        </p>
        <p>
         One study, as an example, evaluated 237 patients with newly diagnosed Graves' hyperthyroidism who were treated with thionamides [
         <a href="#rid1">
          1
         </a>
         ]. At initial presentation, the majority (73.7 percent) of patients had no ocular involvement, whereas mild, moderate-to-severe, and sight-threatening orbitopathy were present in 20, 5.8, and 0.3 percent of patients, respectively. During the 18-month follow-up period, progression to moderate-to-severe orbitopathy occurred in 2.6 percent of patients with no orbitopathy at baseline and in 2.4 percent of patients with mild activity at baseline. In contrast, 58 percent of patients with mild disease at baseline experienced complete remission.
        </p>
        <p>
         The variable severity and course make it difficult to reach conclusions about the efficacy of treatment in the absence of well-controlled clinical trials. (See
         <a class="local">
          'Initial medical therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3195641068">
         <span class="h1">
          MULTIDISCIPLINARY APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of patients with thyroid eye disease involves a multidisciplinary approach and includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reversal of hyperthyroidism, if present
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitoring for and prompt treatment of hypothyroidism, occurring as a consequence of treating hyperthyroidism
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cessation of smoking, if applicable
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Local measures to reduce ocular surface irritation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of inflammation and swelling in the periorbital tissues
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitoring for the development of sight-threatening disease
        </p>
        <p>
        </p>
        <p>
         Patients with thyroid eye disease should be treated according to the severity of their eye disease  (
         <a class="graphic graphic_table graphicRef116360" href="/z/d/graphic/116360.html" rel="external">
          table 1
         </a>
         ), keeping in mind its natural history. Most patients have mild disease, with no progression during follow-up, and may be treated with local measures alone [
         <a href="#rid1">
          1-4
         </a>
         ] (see
         <a class="local">
          'Local measures'
         </a>
         below). Patients with moderate-to-severe orbitopathy frequently require immunomodulatory therapy, and those with sight-threatening orbitopathy frequently require surgical intervention. (See
         <a class="local">
          'Initial medical therapy'
         </a>
         below and
         <a class="local">
          'Sight-threatening disease'
         </a>
         below.)
        </p>
        <p>
         The multidisciplinary treatment strategy outlined below is largely consistent with guidelines from the American Thyroid Association (ATA) [
         <a href="#rid5">
          5
         </a>
         ], European Thyroid Association [
         <a href="#rid5">
          5
         </a>
         ], and European Group on Graves' Orbitopathy (EUGOGO) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2178920039">
         <span class="h1">
          GENERAL MEASURES FOR MOST PATIENTS
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Reversal of hyperthyroidism, if present
         </span>
         <span class="headingEndMark">
          —
         </span>
         Euthyroidism should be restored in all patients with hyperthyroidism. (See
         <a class="medical medical_review" href="/z/d/html/7872.html" rel="external">
          "Graves' hyperthyroidism in nonpregnant adults: Overview of treatment", section on 'Treatment options'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reduction of thyroid hormone synthesis
         </strong>
         – Reducing thyroid hormone secretion does not improve the pathology of thyroid eye disease, although it does decrease eyelid retraction and stare. Hypothyroidism, when it develops as a result of total thyroidectomy or radioiodine therapy for the treatment of hyperthyroidism, can cause more fluid retention and may have an adverse effect on the orbital pathology. Therefore, during and after treatment of hyperthyroidism, patients require monitoring for and prompt treatment of hypothyroidism. (See
         <a class="medical medical_review" href="/z/d/html/7872.html" rel="external">
          "Graves' hyperthyroidism in nonpregnant adults: Overview of treatment", section on 'Monitoring after treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of hyperthyroidism therapy in patients with active thyroid eye disease
         </strong>
         – Treatment with thionamides or thyroidectomy do not appear to have a negative influence on the course of thyroid eye disease [
         <a href="#rid7">
          7,8
         </a>
         ]. Treatment with one of these modalities is usually followed by a fall in serum thyrotropin receptor antibody (TRAb) concentrations, suggesting a waning of autoimmunity. Radioiodine therapy, however, is more likely to lead to the development or worsening of eye disease than thionamides or surgery [
         <a href="#rid7">
          7,9-12
         </a>
         ], and it is associated with an increase in TRAb  (
         <a class="graphic graphic_figure graphicRef115288" href="/z/d/graphic/115288.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid13">
          13
         </a>
         ]. Thus, moderate-to-severe or sight-threatening eye disease is a contraindication to radioiodine therapy. (See
         <a class="medical medical_review" href="/z/d/html/7879.html" rel="external">
          "Radioiodine in the treatment of hyperthyroidism", section on 'Radioiodine and thyroid eye disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Moderate-to-severe or sight-threatening thyroid eye disease
         </strong>
         – For patients with active and moderate-to-severe or sight-threatening eye disease, thionamides or surgery are the preferred treatment options. Patients who refuse surgery and who have had adverse reactions to thionamides may need to be offered radioiodine therapy with glucocorticoid coverage. (See
         <a class="medical medical_review" href="/z/d/html/7879.html" rel="external">
          "Radioiodine in the treatment of hyperthyroidism", section on 'Glucocorticoids in patients with thyroid eye disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild thyroid eye disease
         </strong>
         – Patients with active, mild thyroid eye disease are still candidates for thionamides, radioiodine, or surgery, although many clinicians avoid radioiodine in the presence of mild eye disease. If radioiodine is chosen, glucocorticoids should be administered concurrently to prevent deterioration of orbitopathy  (
         <a class="graphic graphic_table graphicRef110053" href="/z/d/graphic/110053.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7879.html" rel="external">
          "Radioiodine in the treatment of hyperthyroidism", section on 'Glucocorticoids in patients with thyroid eye disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients treated surgically, total thyroidectomy by an experienced thyroid surgeon is the procedure of choice. Total thyroidectomy eliminates more thyroid antigens than subtotal thyroidectomy, resulting in progressive decreases in antibodies to all major thyroid antigens and especially to the thyrotropin receptor [
         <a href="#rid13">
          13,14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7880.html" rel="external">
          "Surgical management of hyperthyroidism", section on 'Extent of resection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1648324873">
         <span class="h2">
          Smoking cessation
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients should be advised to discontinue smoking as cigarette smoking increases the incidence of symptomatic thyroid eye disease, increases the risk of worsening orbitopathy after radioiodine [
         <a href="#rid12">
          12
         </a>
         ], and also renders patients more refractory to antiinflammatory therapy [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7825.html" rel="external">
          "Clinical features and diagnosis of thyroid eye disease", section on 'Risk factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2032524398">
         <span class="h2">
          Local measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients should be advised of local measures to improve symptoms. Local measures include
         <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">
          artificial tears
         </a>
         (typically
         <a class="drug drug_general" data-topicid="10153" href="/z/d/drug information/10153.html" rel="external">
          methylcellulose
         </a>
         eye drops) and raising the head of the bed at night (theoretically to reduce orbital congestion). Photophobia and sensitivity to wind or cold air are often relieved by use of dark glasses and instillation of artificial tears every two to three hours during the day. Lubricants or ointments, such as petrolatum jelly and lid taping can be used at night. Eye patching or prisms incorporated into spectacles are also useful temporizing measures to treat diplopia while awaiting eye muscle stability before strabismus surgery.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          ADDITIONAL TREATMENT ACCORDING TO SEVERITY OF ORBITOPATHY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional treatment of thyroid eye disease should be tailored according to the severity of the eye disease  (
         <a class="graphic graphic_table graphicRef116360" href="/z/d/graphic/116360.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2194419143">
         <span class="h2">
          Mild disease
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Local measures
         </strong>
         – For patients with mild eye involvement (mild chemosis, mild-to-moderate eyelid swelling, absence of significant proptosis [often cited as &lt;3 mm above upper limit of normal for race], no or intermittent diplopia, corneal exposure responsive to lubricants), local measures often lead to sufficient relief of eye symptoms, and no additional treatment is needed. (See
         <a class="local">
          'Local measures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selenium
         </strong>
         – Some UpToDate authors and editors suggest a six-month trial of
         <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">
          selenium
         </a>
         (100 mcg twice daily) in patients with mild orbitopathy, while others would not suggest selenium for patients residing in selenium-replete areas, such as the United States.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a double-blind, placebo-controlled trial,
         <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">
          selenium
         </a>
         (100 mcg twice daily) for six months significantly improved soft-tissue swelling and quality-of-life measures [
         <a href="#rid17">
          17
         </a>
         ]. Based on these results, European Group on Graves' Orbitopathy (EUGOGO) recommends a six-month course of selenium for patients with mild and active orbitopathy of relatively short duration [
         <a href="#rid6">
          6
         </a>
         ]. Since participating centers in the selenium trial were located in areas of relative selenium insufficiency, it is not known whether similar results would be found in selenium-rich regions (eg, most of the United States). There were no adverse effects of selenium treatment in any of the thyroid eye disease studies, but selenium use has been associated with an increased risk of developing type 2 diabetes mellitus [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1771.html" rel="external">
          "Type 2 diabetes mellitus: Prevalence and risk factors", section on 'Selenium'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2585.html" rel="external">
          "Overview of dietary trace elements", section on 'Selenium'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">
          Selenium
         </a>
         supplementation may also decrease inflammatory activity in patients with autoimmune thyroiditis, as evidenced by a fall in thyroid antibody levels, and may also reduce the risk of postpartum thyroiditis in women who are positive for thyroid peroxidase (TPO) antibodies. (See
         <a class="medical medical_review" href="/z/d/html/7831.html" rel="external">
          "Postpartum thyroiditis", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1229418764">
         <span class="h2">
          Moderate-to-severe disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients should be advised of local measures to improve symptoms (see
         <a class="local">
          'Local measures'
         </a>
         above). Most patients with moderate-to-severe disease  (
         <a class="graphic graphic_table graphicRef116360" href="/z/d/graphic/116360.html" rel="external">
          table 1
         </a>
         ) will require additional therapy.
        </p>
        <p class="headingAnchor" id="H370578145">
         <span class="h3">
          Initial medical therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with moderate-to-severe orbitopathy, we suggest initial treatment with either
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          teprotumumab
         </a>
         or glucocorticoids. In the absence of comparative effectiveness trials, the choice of therapy should be individualized based upon the specific clinical features of the patient, shared decision-making, regional expertise, and availability of therapies.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients presenting primarily with severe inflammation and periorbital edema, in the absence of significant proptosis or diplopia
         </strong>
         – In the presence
         <em>
         </em>
         of severe inflammation and periorbital edema (ie, active disease  (
         <a class="graphic graphic_table graphicRef116361" href="/z/d/graphic/116361.html" rel="external">
          table 3
         </a>
         )) and the absence of significant proptosis or diplopia, we prefer initial treatment with glucocorticoids. Intravenous (IV) glucocorticoids are generally preferred, but if not available, oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         may be substituted [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients presenting with proptosis, soft tissue involvement, and/or diplopia
         </strong>
         – In the presence of proptosis, soft tissue involvement, and/or diplopia, we prefer initial treatment with
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          teprotumumab
         </a>
         (if available). If not available, treatment with glucocorticoids is reasonable. (See
         <a class="local">
          'Teprotumumab'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         For patients with moderate-to-severe orbitopathy, the initial treatment for many years has been with glucocorticoids, despite their many side effects. Glucocorticoids have a long track record supported by multiple lines of evidence (but sparse placebo-controlled trial data) and a known risk-to-benefit ratio [
         <a href="#rid19">
          19-23
         </a>
         ]. In general, glucocorticoids provide improvement in active inflammation and less pronounced long-term improvement in proptosis or diplopia.
        </p>
        <p>
         Some experts now advocate for broader use of
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          teprotumumab
         </a>
         (an insulin-like growth factor 1 [IGF-1] monoclonal blocking antibody), as a first-line medical therapy [
         <a href="#rid24">
          24
         </a>
         ], although it is not available in Europe and many other countries. It is also very expensive (in excess of $300,000 USD for eight infusions), third-party payer coverage of this drug is variable, and preauthorization is often required. The European guidelines suggest IV glucocorticoids as monotherapy or in combination with oral
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         (in the absence of teprotumumab being available) for people with moderate-to-severe and active thyroid eye disease [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         There is only indirect information on comparative efficacy of
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          teprotumumab
         </a>
         with glucocorticoids, the standard therapy for patients with moderate-to-severe orbitopathy [
         <a href="#rid25">
          25
         </a>
         ], and limited safety data (see
         <a class="local">
          'Teprotumumab'
         </a>
         below). Nevertheless, teprotumumab remains the only drug that has shown to result in significant improvement in proptosis. This effect is most likely secondary to inducing apoptosis of the retro-orbital fibroblasts and adipocytes [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
         As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Short duration, active thyroid eye disease
         </strong>
         – In two 24-week trials comparing
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          teprotumumab
         </a>
         with placebo in 171 patients with active, moderate-to-severe orbitopathy diagnosed within nine months of trial entry (mean clinical activity score 5.2), a greater proportion of patients in the teprotumumab group had a reduction in clinical activity score and degree of proptosis (69 versus 20 percent with placebo and 78 versus 7 percent with placebo, respectively) [
         <a href="#rid28">
          28-30
         </a>
         ]. The durability of the impressive initial response with teprotumumab compared with placebo is not well established. In the clinical trials, approximately 20 to 30 percent of patients failed to meet study definitions for response to therapy, and some responders experienced relapse [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic, less active thyroid eye disease
         </strong>
         – There are limited data on the efficacy of
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          teprotumumab
         </a>
         in patients with longer duration, less active disease [
         <a href="#rid33">
          33
         </a>
         ]. In a trial of teprotumumab or placebo in 62 patients with chronic thyroid eye disease (mean duration 5.2 years, mean clinical activity score 0.4), a greater proportion of patients in the teprotumumab group had a reduction in proptosis (61.9 versus 25 percent in the placebo group), with a mean proptosis reduction of 2.41 mm in the teprotumumab group versus 0.92 mm with placebo [
         <a href="#rid34">
          34
         </a>
         ]. In a retrospective analysis of 31 patients with a mean disease duration of 81 months (mean clinical activity score 2.3) who had received at least three infusions of teprotumumab, 90 percent experienced proptosis reduction by ≥2 mm [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H167842455">
         <span class="h3">
          Administration of initial therapies
         </span>
        </p>
        <p class="headingAnchor" id="H472030470">
         <span class="h4">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         IV
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         pulse therapy is preferred to oral dosing when available. IV therapy has the advantage of fewer side effects than high oral doses of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         [
         <a href="#rid36">
          36-38
         </a>
         ]. IV methylprednisolone is given in a dose of 500 mg once weekly for weeks 1 to 6, then 250 mg once weekly for weeks 7 to 12 with cumulative dose 4.5 to 5 g over 12 weeks. In one small trial with identical cumulative IV methylprednisolone doses (4.5 g over 12 weeks), the efficacy and safety of monthly and weekly dosing were similar [
         <a href="#rid23">
          23
         </a>
         ]. Very high IV doses (cumulative doses greater than 8 g) have been seen to induce liver failure and must be avoided [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         If infusion therapy is not available or the patient refuses IV therapy, high dose of oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (eg, 60 to 100 mg/day) is an alternative [
         <a href="#rid36">
          36,39-41
         </a>
         ]. In less severe disease, one UpToDate author first administers 30 mg/day before increasing to higher doses as needed.
        </p>
        <p>
         In systematic reviews and meta-analyses of trials comparing treatments of thyroid eye disease, IV pulse glucocorticoids were more effective than oral glucocorticoids in reducing symptoms (overall response rate 82 versus 53 percent) [
         <a href="#rid19">
          19,36
         </a>
         ]. The advantage was mostly due to improvements in patients with more severe disease [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         As an example, in a trial of 70 euthyroid patients with untreated, severe thyroid eye disease randomly assigned to receive once-weekly IV
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (0.5 g, then 0.25 g, weekly for six weeks each) or a high dose of oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (100 mg per day, tapering by 10 mg per week), the following results were seen [
         <a href="#rid39">
          39
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At three months, 27 of 35 patients (77 percent) in the IV group had a treatment response compared with 18 of 35 (51 percent) in the oral group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improvements over baseline for visual acuity, chemosis, and quality of life were greater in the IV group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Additional treatment was required less frequently in the IV group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adverse events were less frequent with IV glucocorticoids.
        </p>
        <p>
        </p>
        <p>
         Improvement usually occurs within four weeks. Approximately one-half of patients have a good response to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         by the end of six months; those patients with less muscle swelling are more likely to respond [
         <a href="#rid42">
          42
         </a>
         ]. However, given the many side effects of prolonged high-dose prednisone treatment, other approaches should be considered if the patient does not respond in four to six weeks (see
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         ). If a good response occurs, the daily dose should be decreased to the lowest dose at which improvement is maintained. In some patients, the eye disease worsens when the dose of prednisone is reduced.
        </p>
        <p>
         Patients taking long-term glucocorticoids require a skeletal assessment to identify individuals at high risk for fracture who would benefit from intervention. This is particularly important in postmenopausal women. This topic is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2032.html" rel="external">
          "Clinical features and evaluation of glucocorticoid-induced osteoporosis", section on 'Evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H798504141">
         <span class="h4">
          Teprotumumab
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         –
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          Teprotumumab
         </a>
         is administered every three weeks as an IV infusion (10 mg/kg initial dose, then 20 mg/kg) for a total of eight infusions [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Nausea (17 versus 9 percent), diarrhea (12 versus 8 percent), muscle spasms (25 versus 7 percent), hyperglycemia (10 versus 1 percent), and hearing impairment (10 to 15 versus 0 percent) were reported more frequently in the
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          teprotumumab
         </a>
         group [
         <a href="#rid29">
          29,31,43,44
         </a>
         ]. Other adverse reactions that occurred more commonly with teprotumumab included alopecia, fatigue, dysgeusia, headache, and dry skin. Patients with type 2 diabetes may experience deterioration in glycemic control [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a systematic review of adverse effects, 7 to 81 percent of patients with thyroid eye disease reported hearing changes (eg, ear fullness, pressure, tinnitus, hearing loss) after a mean of 3.8
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          teprotumumab
         </a>
         infusions [
         <a href="#rid45">
          45
         </a>
         ]. Audiograms were not routinely performed. In a subsequent observational study evaluating hearing outcomes following teprotumumab therapy, 21 percent (11 of 52 patients) had a decline in hearing on audiometry immediately after completing therapy [
         <a href="#rid46">
          46
         </a>
         ]. A decrease in hearing was more common in patients with baseline hearing dysfunction (10 of the 11 patients). After six months follow-up, 5 of 11 patients had persistent changes on audiometry.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – It is important to discuss potential adverse events prior to initiating therapy and review symptoms at each visit. The approach to monitoring for hyperglycemia and hearing loss varies. It is reasonable to obtain baseline audiometry and repeat in individuals who report any change in hearing. Some experts measure glucose prior to each infusion (either venipuncture or capillary glucose with a glucometer) and suggest more frequent glucose assessments in patients who develop symptoms of hyperglycemia or who are at high risk for developing hyperglycemia (eg, history of prediabetes, older age) [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications
         </strong>
         –
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          Teprotumumab
         </a>
         is contraindicated during pregnancy and in children, settings in which interference with growth hormone-IGF-1 activity would be harmful [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2253696125">
         <span class="h3">
          Contraindications, intolerance, or lack of response to initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         If there is no initial response to the first few doses of glucocorticoid
         <em>
          s
         </em>
         and a decision is made to proceed with alternative medical therapy, we suggest
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          teprotumumab
         </a>
         (if available), although there are no clinical trial data examining the efficacy of teprotumumab in patients with glucocorticoid-refractory eye disease. Observational data suggest teprotumumab is effective in patients with persistent eye disease after treatment with glucocorticoids and/or orbital radiation [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         If both
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          teprotumumab
         </a>
         and high-dose glucocorticoid therapy are contraindicated, cannot be tolerated, or are ineffective, options include other medical immunosuppressive therapies (eg,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         ), external orbital radiation, or orbital decompression surgery. (See
         <a class="local">
          'Secondary medical therapies'
         </a>
         below and
         <a class="local">
          'External orbital radiation'
         </a>
         below and
         <a class="local">
          'Orbital decompression surgery'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3723997556">
         <span class="h4">
          Secondary medical therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are few direct comparison trials to guide the selection of secondary therapies. Trial data also show efficacy for
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         (an interleukin 6 [IL-6] antibody) compared with placebo in glucocorticoid refractory thyroid eye disease [
         <a href="#rid49">
          49
         </a>
         ],
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         compared with IV glucocorticoids [
         <a href="#rid50">
          50
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil compared with IV glucocorticoids [
         <a href="#rid51">
          51
         </a>
         ]. As with choosing initial medical therapy, the selection of secondary therapies should be individualized based upon the clinical presentation of the patient, shared decision-making, regional expertise, and availability of therapies.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tocilizumab
         </strong>
         –
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          Tocilizumab
         </a>
         targets IL-6 and has been used in patients with rheumatoid arthritis. It has also been investigated for the treatment of patients with thyroid eye disease who are not improving with glucocorticoids [
         <a href="#rid49">
          49,52
         </a>
         ]. In a randomized trial, 32 patients with thyroid eye disease were randomly assigned to tocilizumab (8 mg/kg) or placebo IV at 0, 4, 8, and 12 weeks [
         <a href="#rid49">
          49
         </a>
         ]. Treatment with tocilizumab was associated with greater improvement in clinical activity score at 16 weeks (93.3 versus 58.8 percent with placebo) and improvement in a composite ophthalmic score at 16 weeks (73.3 versus 29.4 percent), but no significant differences between groups at 40 weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rituximab
         </strong>
         – In observational studies,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , a powerful anti-B cell monoclonal antibody, has been reported to be as effective as glucocorticoids without the glucocorticoid-related side effects [
         <a href="#rid53">
          53-56
         </a>
         ]. Rituximab induces a fall in thyrotropin receptor antibody (TRAb) levels [
         <a href="#rid57">
          57
         </a>
         ] and depletion of B cells in the retro-orbital tissues, not just the periphery [
         <a href="#rid58">
          58
         </a>
         ]. Although high doses of this antibody may be associated with severe side effects from the profound immunosuppression that ensues, lower doses (two infusions of 1000 mg each, one to two months apart) may be effective in thyroid eye disease and allow severe immunosuppression to be avoided.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Two trials evaluating
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         therapy (total dose 500 to 2000 mg) for thyroid eye disease showed conflicting results, although patients differed in disease severity and duration in these studies [
         <a href="#rid50">
          50,59
         </a>
         ]. The selection of patients for rituximab therapy is important, as patients with severe, new-onset thyroid eye disease may be those who benefit most from this approach. The trial that showed the effectiveness of rituximab treated the disease earlier in its evolution and included more severely affected patients, while the negative trial studied patients with milder signs later in the course of their disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Both studies showed a high rate of adverse effects from
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , including new optic neuropathy and infusion reactions. Very low-dose rituximab (single infusion of 100 mg) appears to be effective in active, moderate-to-severe thyroid eye disease and may reduce adverse effects [
         <a href="#rid60">
          60
         </a>
         ]. The therapeutic benefit of rituximab, however, remains uncertain despite the seemingly logical action of the approach.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycophenolate
         </strong>
         <strong>
          mofetil
         </strong>
         –
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          Mycophenolate
         </a>
         mofetil is under investigation for the treatment of thyroid eye disease, either alone or in combination with glucocorticoids [
         <a href="#rid51">
          51,61
         </a>
         ]. Although many endocrine specialists are wary of using such a powerful immunosuppressant requiring careful initial monitoring, it is a well-tolerated drug.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a trial comparing
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (500 mg twice a day for 24 weeks) with glucocorticoids (0.5 g IV daily for three days [two consecutive weeks] followed by 60 mg oral daily for eight weeks and then tapered) in 174 Chinese patients with active, moderate-to-severe thyroid eye disease, the overall response at 24 weeks was better with mycophenolate (91.3 versus 67.9 percent) [
         <a href="#rid51">
          51
         </a>
         ]. In a second trial comparing IV glucocorticoids alone to glucocorticoids plus mycophenolate mofetil, the response rate in the monotherapy versus the combination group at 12 and 24 weeks was 49 versus 63 percent and 53 versus 71 percent, respectively. Only the 24-week findings were statistically significant. A sustained response at 36 weeks occurred in 46 and 67 percent, respectively [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          Mycophenolate
         </a>
         is a strong immunosuppressive with relatively mild side effects, widely used after transplantation [
         <a href="#rid61">
          61,63
         </a>
         ]. It is a potent, selective, noncompetitive, and reversible inhibitor of inosine-5'-monophosphate dehydrogenase [
         <a href="#rid63">
          63
         </a>
         ]. By depleting guanosine and deoxyguanosine nucleotides in T and B lymphocytes, it inhibits their proliferation and reduces immunoglobulin in production. This drug also suppresses dendritic cell maturation, decreasing its capacity for antigen presentation to T lymphocytes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1563137271">
         <span class="h4">
          External orbital radiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         External radiation is used infrequently, possibly because of retinal side effects seen early in its introduction, as well as questionable long-term beneficial effects from this modality. Furthermore, the availability of alternative secondary therapeutics has made the approach less useful. It is still sometimes used in patients with moderate-to-severe eye disease in whom IV glucocorticoids are contraindicated, cannot be tolerated, or are ineffective.
        </p>
        <p>
         In theory, radiotherapy kills retro-orbital T cells. The usual dose for treatment of the retro-orbital area is 2000 rads (20 Gy), administered in 10 fractions of 200 rads (2 Gy) over two weeks. However, the value of orbital radiation alone remains controversial. In two trials, it was more effective than glucocorticoid therapy [
         <a href="#rid37">
          37,64
         </a>
         ]; however, two additional trials comparing orbital radiation with sham irradiation found no benefit [
         <a href="#rid65">
          65,66
         </a>
         ], and in a meta-analysis of three trials, orbital radiation was no better than sham radiation for improvement in clinical activity score but was better for diplopia [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         In contrast, trials of combined radiation and glucocorticoid therapy have suggested that the combination may be more effective than either alone [
         <a href="#rid19">
          19,67,68
         </a>
         ]. In a randomized trial of 82 patients with thyroid eye disease treated with high-dose IV or oral glucocorticoid (combined with orbital radiation), the IV route was more effective, better tolerated, and associated with fewer side effects [
         <a href="#rid40">
          40
         </a>
         ]. Thus, if combined therapy is used, IV glucocorticoids may be preferable.
        </p>
        <p>
         It is unclear whether orbital radiation provides lasting benefit. In one randomized trial, radiotherapy was effective in improving eye muscle motility and decreasing the severity of diplopia, but it did not prevent subsequent worsening of orbitopathy [
         <a href="#rid69">
          69
         </a>
         ]. In the same trial, orbital radiotherapy did not improve quality of life or management costs [
         <a href="#rid69">
          69
         </a>
         ]. Although orbital radiation improved diplopia significantly compared with sham irradiation in one trial, most irradiated patients still required strabismus surgery to correct extraocular muscle dysfunction. In addition, retro-orbital irradiation has been reported to have serious, long-term side effects when used alone. Potential side effects reported in 204 patients with a mean follow-up of 11 years included cataracts in 18 percent treated with a cobalt unit and 8 percent treated by linear accelerator (compared with the general population, the rates were not significantly elevated in patients under age 60 years) and mild retinopathy in 14 percent of patients with diabetes and hypertension [
         <a href="#rid70">
          70
         </a>
         ]. Transient blindness can also occur due to inadvertent injury to the optic nerve [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1686785674">
         <span class="h3">
          Other medical therapies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Statins
         </strong>
         – Statins have been shown to have a protective effect on the development of thyroid eye disease [
         <a href="#rid72">
          72
         </a>
         ] and a potential therapeutic benefit in patients with thyroid eye disease [
         <a href="#rid73">
          73
         </a>
         ]. As an example, in one trial, 119 patients with moderate-to-severe thyroid eye disease and hypercholesterolemia were randomly assigned to receive oral
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         for 12 weeks or no statin [
         <a href="#rid73">
          73
         </a>
         ]. All patients were treated with
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         . After 24 weeks, orbitopathy outcome became improved in 51 percent of individuals in the atorvastatin group compared with 28 percent in the control group. Additional studies are warranted.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2321769096">
         <span class="h2">
          Sight-threatening disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sight-threatening thyroid eye disease occurs in 1 to 2 percent of patients with Graves' disease [
         <a href="#rid74">
          74
         </a>
         ]. Threatened loss of vision, often preceded by loss of color vision, is an
         <strong>
          ophthalmologic emergency
         </strong>
         . Close and coordinated observation of the effects of medical therapy and the progress of the disease is necessary to determine whether and when a surgical approach to treatment is needed in the patient with visual loss. Decompression surgery almost invariably halts the progress of the disease and preserves vision if performed in time and with expertise. How the use of the newer medical therapies (eg,
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          teprotumumab
         </a>
         ) will change these approaches remains to be seen [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H770594195">
         <span class="h3">
          IV glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with sight-threatening eye disease should receive immediate glucocorticoid therapy, preferably IV (eg,
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         , 0.5 to 1 g daily for either three consecutive days or on every second day), and should be hospitalized for possible urgent orbital decompression surgery if the response is inadequate. This approach is in agreement with European guidelines [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="local">
          'Orbital decompression surgery'
         </a>
         below.)
        </p>
        <p>
         Clinical outcome appears to be better if decompression surgery is performed after rather than before glucocorticoid therapy. This was illustrated in a small trial of 15 patients randomly assigned to initial therapy with IV
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         or orbital decompression [
         <a href="#rid76">
          76
         </a>
         ]. In the group of patients who initially received surgery, 83 percent subsequently required methylprednisolone, and some also required orbital irradiation, while 56 percent of the patients initially treated with methylprednisolone required surgery or orbital irradiation.
        </p>
        <p class="headingAnchor" id="H1625119579">
         <span class="h3">
          Orbital decompression surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         With the advent effective medical therapy (eg,
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          teprotumumab
         </a>
         ) to reduce proptosis and muscle volume, it is likely that fewer patients will require orbital decompression surgery.
        </p>
        <p>
         Indications for orbital decompression surgery include [
         <a href="#rid77">
          77
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Optic neuropathy caused by enlarged extraocular muscles not responsive to high-dose corticosteroids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe orbital inflammation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excessive proptosis leading to exposure keratitis, corneal ulceration, or debilitating cosmetic defect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pain relief.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Progressive orbitopathy not responding to other measures.
        </p>
        <p>
        </p>
        <p>
         The orbit may be decompressed by removing the lateral wall, the roof, or the medial wall and the floor [
         <a href="#rid78">
          78,79
         </a>
         ]. Our experience has been with the last procedure, known as transantral decompression, in which the surgeon removes the floor and medial wall of the orbit to allow decompression  (
         <a class="graphic graphic_figure graphicRef93211" href="/z/d/graphic/93211.html" rel="external">
          figure 2
         </a>
         ). In addition, it does not leave a scar on the face and avoids craniotomy.
        </p>
        <p>
         An excellent result can usually be achieved, with substantial reduction in proptosis and edema. However, diplopia usually does not improve and may worsen, so that eye muscle surgery is almost always needed later.
        </p>
        <p>
         In a series of 78 patients who had transantral or endonasal decompression [
         <a href="#rid80">
          80
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Proptosis was reduced by 4.4 to 4.7 mm (left and right eyes)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Visual acuity improved in 44 to 55 percent and worsened in 18 to 20 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diplopia persisted in 50 percent but was improved in 54 percent
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1423072419">
         <span class="h2">
          Nonurgent cosmetic surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Occasional patients require plastic surgery to correct marked periorbital edema, while many others choose to have cosmetic correction of relatively mild edema.
         <em>
         </em>
         Surgery for a cosmetic correction should wait until the disease enters its quiescent stages or it may precipitate a worsening of the inflammation.
        </p>
        <p>
         Fat decompression surgery (removing the retro-orbital adipose tissue) has been performed for many years and can produce a cosmetic correction in patients with moderate thyroid eye disease and significant proptosis [
         <a href="#rid81">
          81
         </a>
         ]. Bilateral, lateral tarsorrhaphy may also be performed to minimize or prevent corneal damage in patients who have severe proptosis and cannot close their eyes. Surgical recession of Muller's muscle and the levator will correct upper lid retraction. However, decompression surgery is preferable for both of these problems because it is more effective both functionally and cosmetically. For patients requiring both strabismus surgery and orbital decompression, the decompression should be performed first, followed by strabismus surgery.
        </p>
        <p class="headingAnchor" id="H2080402530">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109107.html" rel="external">
          "Society guideline links: Hyperthyroidism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17628836">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multidisciplinary approach
         </strong>
         – Patients with thyroid eye disease should be treated according to disease severity  (
         <a class="graphic graphic_table graphicRef116360" href="/z/d/graphic/116360.html" rel="external">
          table 1
         </a>
         ), keeping in mind that most patients have mild disease and do not have progression during follow-up. Treatment involves a multidisciplinary approach and includes reversal of hyperthyroidism (if present), smoking cessation, local measures to reduce ocular surface irritation, reduction of inflammation in the periorbital tissues, and monitoring for the development of sight-threatening disease. (See
         <a class="local">
          'Multidisciplinary approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General measures
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Reversal of hyperthyroidism, if present
         </strong>
         – Euthyroidism should be restored in all patients with hyperthyroidism. Treatment with thionamides or thyroidectomy do not appear to have a negative influence on the course of thyroid eye disease, whereas radioiodine is more likely to lead to the development or worsening of eye disease. (See
         <a class="local">
          'Reversal of hyperthyroidism, if present'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7879.html" rel="external">
          "Radioiodine in the treatment of hyperthyroidism", section on 'Radioiodine and thyroid eye disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Smoking cessation
         </strong>
         – All patients should be strongly advised to discontinue smoking as cigarette smoking increases the incidence of symptomatic thyroid eye disease, increases the risk of worsening orbitopathy after radioiodine, and reduces the efficacy of glucocorticoid therapy. (See
         <a class="local">
          'Smoking cessation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7825.html" rel="external">
          "Clinical features and diagnosis of thyroid eye disease", section on 'Risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Local measures for all patients
         </strong>
         – Local measures to improve symptoms include lubricating eye drops, raising the head of the bed at night, and eye patching or prisms for diplopia. Photophobia and sensitivity to wind or cold air are often relieved by use of dark glasses and instillation of lubricating eye drops every two to three hours during the day and of lubricating ointments or lid taping at night. (See
         <a class="local">
          'Local measures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild orbitopathy
         </strong>
         – For patients with mild orbitopathy, local measures are usually effective to relieve eye symptoms, and no additional treatment is needed. Some UpToDate authors and editors suggest a six-month trial of
         <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">
          selenium
         </a>
         in patients with mild orbitopathy, while others would not suggest selenium for patients residing in selenium-replete areas, such as the United States. (See
         <a class="local">
          'Mild disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate-to-severe orbitopathy
         </strong>
         – For patients with moderate-to-severe orbitopathy, we suggest initial treatment with either
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          teprotumumab
         </a>
         or glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In the absence of comparative effectiveness trials, the choice of therapy should be individualized based upon the clinical presentation of the patient, shared decision-making, regional expertise, and availability of therapies. (See
         <a class="local">
          'Moderate-to-severe disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients presenting primarily
         </strong>
         <strong>
          with
         </strong>
         <strong>
          severe inflammation and periorbital edema, in the absence of significant proptosis or diplopia
         </strong>
         – In the presence
         <em>
         </em>
         of severe inflammation and periorbital edema (ie, active disease  (
         <a class="graphic graphic_table graphicRef116361" href="/z/d/graphic/116361.html" rel="external">
          table 3
         </a>
         )) and the absence of significant proptosis or diplopia, we prefer initial treatment with glucocorticoids. Intravenous (IV) glucocorticoids are generally preferred, but if not available, oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         may be used. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Proptosis, soft tissue involvement, and/or diplopia
         </strong>
         – In the presence of proptosis, soft tissue involvement, and/or diplopia, we prefer initial treatment with
         <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">
          teprotumumab
         </a>
         infusions (if available). If not available, treatment with glucocorticoids is reasonable. (See
         <a class="local">
          'Teprotumumab'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If first-line therapy is contraindicated, cannot be tolerated, or is ineffective, options include other medical therapies, external orbital radiation, or orbital decompression surgery. The choice of therapy should be individualized based upon shared decision-making, regional expertise, availability of therapies, and cost. Alternative medical therapies include
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil. (See
         <a class="local">
          'Contraindications, intolerance, or lack of response to initial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sight-threatening orbitopathy
         </strong>
         – Patients with sight-threatening orbitopathy should receive immediate glucocorticoid therapy (eg, IV
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         , 0.5 to 1 g daily for either three consecutive days or on every second day) and should be hospitalized for possible urgent orbital decompression surgery. (See
         <a class="local">
          'Sight-threatening disease'
         </a>
         above and
         <a class="local">
          'Orbital decompression surgery'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab 2013; 98:1443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piantanida E, Tanda ML, Lai A, et al. Prevalence and natural history of Graves' orbitopathy in the XXI century. J Endocrinol Invest 2013; 36:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menconi F, Profilo MA, Leo M, et al. Spontaneous improvement of untreated mild Graves' ophthalmopathy: Rundle's curve revisited. Thyroid 2014; 24:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies TF, Andersen S, Latif R, et al. Graves' disease. Nat Rev Dis Primers 2020; 6:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burch HB, Perros P, Bednarczuk T, et al. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. Thyroid 2022; 32:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol 2021; 185:G43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tallstedt L, Lundell G, Tørring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992; 326:1733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcocci C, Bruno-Bossio G, Manetti L, et al. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf) 1999; 51:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartalena L, Marcocci C, Bogazzi F, et al. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321:1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sridama V, DeGroot LJ. Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 1989; 87:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gwinup G, Elias AN, Ascher MS. Effect on exophthalmos of various methods of treatment of Graves' disease. JAMA 1982; 247:2135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laurberg P, Wallin G, Tallstedt L, et al. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008; 158:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003; 139:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eckstein A, Quadbeck B, Mueller G, et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 2003; 87:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor PN, Zhang L, Lee RWJ, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol 2020; 16:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves' orbitopathy. N Engl J Med 2011; 364:1920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winther KH, Rayman MP, Bonnema SJ, Hegedüs L. Selenium in thyroid disorders - essential knowledge for clinicians. Nat Rev Endocrinol 2020; 16:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, et al. Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab 2009; 94:2708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu N, Cui Y, Xie T, Zheng M. Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis. J Ophthalmol 2018; 2018:7184163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvi M, Campi I. Medical Treatment of Graves' Orbitopathy. Horm Metab Res 2015; 47:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou X, Zhou D, Wang J, Chen G. Treatment strategies for Graves' ophthalmopathy: a network meta-analysis. Br J Ophthalmol 2020; 104:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Z, Luo Y, Huang Q, et al. A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy. J Clin Endocrinol Metab 2023; 109:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas RS, Wang Y, Dailey RA, et al. Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators. J Neuroophthalmol 2021; 41:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas RS, Dailey R, Subramanian PS, et al. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison. JAMA Ophthalmol 2022; 140:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain AP, Gellada N, Ugradar S, et al. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. Br J Ophthalmol 2022; 106:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morshed SA, Ma R, Latif R, Davies TF. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition. Thyroid 2022; 32:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med 2017; 376:1748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med 2020; 382:341.
          </a>
         </li>
         <li class="breakAll">
          https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease (Accessed on January 22, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol 2021; 9:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study. Ophthalmology 2022; 129:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramanian PS, Cho RI, Kahana A. Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease. Curr Opin Ophthalmol 2023; 34:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas RS, Couch S, Wester ST, et al. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. J Clin Endocrinol Metab 2023; 109:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ugradar S, Kang J, Kossler AL, et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye (Lond) 2022; 36:1553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011; 96:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prummel MF, Wiersinga WM. Medical management of Graves' ophthalmopathy. Thyroid 1995; 5:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy. Lancet Diabetes Endocrinol 2017; 5:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 2005; 90:5234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001; 86:3562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Längericht J, Krämer I, Kahaly GJ. Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application. Ther Adv Endocrinol Metab 2020; 11:2042018820958335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang TC, Huang KM, Hsiao YL, et al. Relationships of orbital computed tomographic findings and activity scores to the prognosis of corticosteroid therapy in patients with Graves' ophthalmopathy. Acta Ophthalmol Scand 1997; 75:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartalena L, Marinò M, Marcocci C, Tanda ML. Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears? J Endocrinol Invest 2022; 45:1455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah SA, Amarikwa L, Sears CM, et al. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study. Ophthalmology 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stan MN, Krieger CC. The Adverse Effects Profile of Teprotumumab. J Clin Endocrinol Metab 2023; 108:e654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas RS, Parunakian E, Tolentino J, et al. A Prospective Study Examining Audiometry Outcomes Following Teprotumumab Treatment for Thyroid Eye Disease. Thyroid 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim S, Patzek S. Teprotumumab for Active Thyroid Eye Disease. N Engl J Med 2020; 382:1958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Men CJ, Amarikwa L, Pham B, et al. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. Am J Ophthalmol 2018; 195:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvi M, Vannucchi G, Currò N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 2015; 100:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ye X, Bo X, Hu X, et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy. Clin Endocrinol (Oxf) 2017; 86:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Bilbao L, Martínez-López D, Revenga M, et al. Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. J Clin Med 2020; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvi M, Vannucchi G, Campi I, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006; 154:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L. The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 2006; 154:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007; 156:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hegedüs L, Smith TJ, Douglas RS, Nielsen CH. Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. Clin Endocrinol (Oxf) 2011; 74:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Fassi D, Banga JP, Gilbert JA, et al. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 2009; 130:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvi M, Vannucchi G, Campi I, et al. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol 2009; 131:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab 2015; 100:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vannucchi G, Campi I, Covelli D, et al. Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy. Thyroid 2021; 31:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riedl M, Kuhn A, Krämer I, et al. Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy. J Endocrinol Invest 2016; 39:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahaly GJ, Riedl M, König J, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 2018; 6:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: An update. Drugs Today (Barc) 2009; 45:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prummel MF, Mourits MP, Blank L, et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993; 342:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mourits MP, van Kempen-Harteveld ML, García MB, et al. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 2000; 355:1505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001; 108:1523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartalena L, Marcocci C, Chiovato L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983; 56:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiersinga WM, Prummel MF. An evidence-based approach to the treatment of Graves' ophthalmopathy. Endocrinol Metab Clin North Am 2000; 29:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab 2004; 89:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcocci C, Bartalena L, Rocchi R, et al. Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 2003; 88:3561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nygaard B, Specht L. Transitory blindness after retrobulbar irradiation of Graves' ophthalmopathy. Lancet 1998; 351:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein JD, Childers D, Gupta S, et al. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol 2015; 133:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanzolla G, Sabini E, Leo M, et al. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. Lancet Diabetes Endocrinol 2021; 9:733.
          </a>
         </li>
         <li class="breakAll">
          http://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/books/NBK279098/ (Accessed on June 30, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sears CM, Wang Y, Bailey LA, et al. Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study. Am J Ophthalmol Case Rep 2021; 23:101111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakelkamp IM, Baldeschi L, Saeed P, et al. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 2005; 63:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garrity JA, Fatourechi V, Bergstralh EJ, et al. Results of transantral orbital decompression in 428 patients with severe Graves' ophthalmopathy. Am J Ophthalmol 1993; 116:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogura JH, Thawley SE. Orbital decompression of exophthalmos. Otolaryngol Clin North Am 1980; 13:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shorr N, Seiff SR. The four stages of surgical rehabilitation of the patient with dysthyroid ophthalmopathy. Ophthalmology 1986; 93:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jernfors M, Välimäki MJ, Setälä K, et al. Efficacy and safety of orbital decompression in treatment of thyroid-associated ophthalmopathy: long-term follow-up of 78 patients. Clin Endocrinol (Oxf) 2007; 67:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garrity JA. Orbital lipectomy (fat decompression) for thyroid eye disease: an operation for everyone? Am J Ophthalmol 2011; 151:399.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7827 Version 23.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23408569" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23587873" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prevalence and natural history of Graves' orbitopathy in the XXI century.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23980907" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Spontaneous improvement of untreated mild Graves' ophthalmopathy: Rundle's curve revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32616746" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Graves' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36480280" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34297684" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1489388" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10583319" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2811943" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2741983" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Treatment of Graves' disease and the course of ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6895919" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Effect on exophthalmos of various methods of treatment of Graves' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9420337" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18166819" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12965943" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12770979" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Impact of smoking on the response to treatment of thyroid associated ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31889140" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21591944" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Selenium and the course of mild Graves' orbitopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32001830" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Selenium in thyroid disorders - essential knowledge for clinicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19491222" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30647961" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26361263" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Medical Treatment of Graves' Orbitopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31272958" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Treatment strategies for Graves' ophthalmopathy: a network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37579198" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33417417" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35175308" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33172865" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34927457" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28467880" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Teprotumumab for Thyroid-Associated Ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31971679" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Teprotumumab for the Treatment of Active Thyroid Eye Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31971679" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Teprotumumab for the Treatment of Active Thyroid Eye Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33865501" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34688699" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37610428" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37925673" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34244669" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Teprotumumab for the treatment of chronic thyroid eye disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21239515" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7580273" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Medical management of Graves' ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27346786" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15998777" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502779" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33403097" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9253980" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Relationships of orbital computed tomographic findings and activity scores to the prognosis of corticosteroid therapy in patients with Graves' ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35403994" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37852417" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37071658" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The Adverse Effects Profile of Teprotumumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37962269" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A Prospective Study Examining Audiometry Outcomes Following Teprotumumab Treatment for Thyroid Eye Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32402170" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Teprotumumab for Active Thyroid Eye Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37972960" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30081019" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25494967" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27484048" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32878150" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16556712" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16645007" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17218723" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20455896" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18964302" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19195932" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25343233" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Randomized controlled trial of rituximab in patients with Graves' orbitopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33234032" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26886940" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29396246" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19834629" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Mycophenolate mofetil: An update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8105213" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10801172" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11535445" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6341388" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10874531" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : An evidence-based approach to the treatment of Graves' ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14715820" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12915636" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Long-term safety of orbital radiotherapy for Graves' ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9504522" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Transitory blindness after retrobulbar irradiation of Graves' ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25502604" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34592164" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34592164" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34113737" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16117821" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8238212" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Results of transantral orbital decompression in 428 patients with severe Graves' ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7367005" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Orbital decompression of exophthalmos.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3703522" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The four stages of surgical rehabilitation of the patient with dysthyroid ophthalmopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17466006" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Efficacy and safety of orbital decompression in treatment of thyroid-associated ophthalmopathy: long-term follow-up of 78 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21335108" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Orbital lipectomy (fat decompression) for thyroid eye disease: an operation for everyone?
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
